Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional pe... حسب Naoya Itoh (6029276)

الموضوعات:

Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. حسب Naoya Itoh (6029276)

الموضوعات:

Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional... حسب Naoya Itoh (6029276)

الموضوعات:

Average purchase costs of 3GCs and all oral antimicrobials per 100 patient-days from Phases 1–4. حسب Naoya Itoh (6029276)

الموضوعات:

Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).... حسب Naoya Itoh (6029276)

الموضوعات:

S1 Dataset - حسب Naoya Itoh (6029276)

الموضوعات:

Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... حسب Naoya Itoh (6029276)

الموضوعات:

Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). حسب Naoya Itoh (6029276)

الموضوعات:

Pop-up for oral 3GC prescription. حسب Naoya Itoh (6029276)

الموضوعات:

Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. حسب Naoya Itoh (6029276)

الموضوعات:

Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. حسب Naoya Itoh (6029276)

الموضوعات:

Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). حسب Naoya Itoh (6029276)

الموضوعات:

Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. حسب Naoya Itoh (6029276)

الموضوعات:

Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. حسب Naoya Itoh (6029276)

الموضوعات:

Patients’ histories are presented in decreasing length of observation and colour coded as red for the days of use or referred use and green for abstinence days. حسب Francesco Lolli (2530471)

الموضوعات:

Negativity ratings (mean ± SE) during <i>attend/negative</i> trials (left) and <i>decrease/negative</i> trials (right) of the emotion regulation task, in the TSD (red) and WR (blue... حسب Anthony R. Stenson (11378981)

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Primary and secondary efficacy end points (intention-to-treat population). حسب Benjamin R. Lewis (22279166)

الموضوعات:

Demographic and clinical characteristics of participants at baseline. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Study-related adverse events. حسب Benjamin R. Lewis (22279166)

الموضوعات: